ES2608656T3 - Inhibidores de quinasa de punto de control 1 para la potenciación de agentes que dañan el ADN - Google Patents
Inhibidores de quinasa de punto de control 1 para la potenciación de agentes que dañan el ADN Download PDFInfo
- Publication number
- ES2608656T3 ES2608656T3 ES10721579.0T ES10721579T ES2608656T3 ES 2608656 T3 ES2608656 T3 ES 2608656T3 ES 10721579 T ES10721579 T ES 10721579T ES 2608656 T3 ES2608656 T3 ES 2608656T3
- Authority
- ES
- Spain
- Prior art keywords
- chk1 inhibitor
- cancer
- dna damaging
- damaging agent
- chk1
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003112 inhibitor Substances 0.000 title claims abstract description 205
- 239000012623 DNA damaging agent Substances 0.000 title claims abstract description 141
- 108091000080 Phosphotransferase Proteins 0.000 title claims description 8
- 102000020233 phosphotransferase Human genes 0.000 title claims description 8
- 102100031081 Serine/threonine-protein kinase Chk1 Human genes 0.000 claims abstract description 213
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 100
- 201000011510 cancer Diseases 0.000 claims abstract description 59
- 238000000034 method Methods 0.000 claims abstract description 18
- 230000003389 potentiating effect Effects 0.000 claims abstract description 12
- 101000777293 Homo sapiens Serine/threonine-protein kinase Chk1 Proteins 0.000 claims description 208
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims description 33
- 229960005277 gemcitabine Drugs 0.000 claims description 33
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 31
- 238000011282 treatment Methods 0.000 claims description 25
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 24
- 239000003795 chemical substances by application Substances 0.000 claims description 24
- 230000006378 damage Effects 0.000 claims description 22
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims description 18
- -1 3aminopiperidin1yl Chemical group 0.000 claims description 16
- 229960004768 irinotecan Drugs 0.000 claims description 16
- 231100000682 maximum tolerated dose Toxicity 0.000 claims description 14
- 206010025323 Lymphomas Diseases 0.000 claims description 12
- WFKAJVHLWXSISD-UHFFFAOYSA-N isobutyramide Chemical compound CC(C)C(N)=O WFKAJVHLWXSISD-UHFFFAOYSA-N 0.000 claims description 12
- 229960003966 nicotinamide Drugs 0.000 claims description 12
- 235000005152 nicotinamide Nutrition 0.000 claims description 12
- 239000011570 nicotinamide Substances 0.000 claims description 12
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 claims description 11
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 11
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 10
- 229960004316 cisplatin Drugs 0.000 claims description 10
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims description 9
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 9
- 229960004964 temozolomide Drugs 0.000 claims description 9
- 206010009944 Colon cancer Diseases 0.000 claims description 8
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims description 8
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims description 8
- 206010033128 Ovarian cancer Diseases 0.000 claims description 8
- 229960000684 cytarabine Drugs 0.000 claims description 8
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims description 7
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 7
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 7
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 7
- 229960004117 capecitabine Drugs 0.000 claims description 7
- 229960004562 carboplatin Drugs 0.000 claims description 7
- 206010017758 gastric cancer Diseases 0.000 claims description 7
- 230000035772 mutation Effects 0.000 claims description 7
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 7
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims description 7
- 229960001756 oxaliplatin Drugs 0.000 claims description 7
- 201000011549 stomach cancer Diseases 0.000 claims description 7
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 7
- BCCUXBGEPLKSEX-UHFFFAOYSA-N 5-methylpyridine-3-carboxamide Chemical compound CC1=CN=CC(C(N)=O)=C1 BCCUXBGEPLKSEX-UHFFFAOYSA-N 0.000 claims description 6
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 claims description 6
- 208000032612 Glial tumor Diseases 0.000 claims description 6
- 206010018338 Glioma Diseases 0.000 claims description 6
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 6
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims description 6
- 229940127093 camptothecin Drugs 0.000 claims description 6
- AIMMVWOEOZMVMS-UHFFFAOYSA-N cyclopropanecarboxamide Chemical compound NC(=O)C1CC1 AIMMVWOEOZMVMS-UHFFFAOYSA-N 0.000 claims description 6
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 claims description 6
- 229940047889 isobutyramide Drugs 0.000 claims description 6
- 208000032839 leukemia Diseases 0.000 claims description 6
- 208000014018 liver neoplasm Diseases 0.000 claims description 6
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims description 6
- 206010004593 Bile duct cancer Diseases 0.000 claims description 5
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 5
- 206010073073 Hepatobiliary cancer Diseases 0.000 claims description 5
- 208000017604 Hodgkin disease Diseases 0.000 claims description 5
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 5
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 5
- 206010060862 Prostate cancer Diseases 0.000 claims description 5
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 5
- 208000026900 bile duct neoplasm Diseases 0.000 claims description 5
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 5
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 claims description 5
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims description 5
- JBSLANHIBKBQGE-UHFFFAOYSA-N 2-cyclopropylacetamide Chemical compound NC(=O)CC1CC1 JBSLANHIBKBQGE-UHFFFAOYSA-N 0.000 claims description 4
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 4
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims description 4
- 206010055113 Breast cancer metastatic Diseases 0.000 claims description 4
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims description 4
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 4
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims description 4
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims description 4
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 4
- 206010057644 Testis cancer Diseases 0.000 claims description 4
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims description 4
- SANOUVWGPVYVAV-UHFFFAOYSA-N isovaleramide Chemical compound CC(C)CC(N)=O SANOUVWGPVYVAV-UHFFFAOYSA-N 0.000 claims description 4
- 201000003120 testicular cancer Diseases 0.000 claims description 4
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 3
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 3
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims description 3
- 229960004397 cyclophosphamide Drugs 0.000 claims description 3
- 229960000752 etoposide phosphate Drugs 0.000 claims description 3
- LIQODXNTTZAGID-OCBXBXKTSA-N etoposide phosphate Chemical compound COC1=C(OP(O)(O)=O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 LIQODXNTTZAGID-OCBXBXKTSA-N 0.000 claims description 3
- 229960002949 fluorouracil Drugs 0.000 claims description 3
- 229960005079 pemetrexed Drugs 0.000 claims description 3
- 230000005855 radiation Effects 0.000 claims description 3
- 229960001278 teniposide Drugs 0.000 claims description 3
- 229960000303 topotecan Drugs 0.000 claims description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 2
- 230000001684 chronic effect Effects 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- 190000008236 carboplatin Chemical compound 0.000 claims 2
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims 1
- 206010027540 Microcytosis Diseases 0.000 claims 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims 1
- 229960000975 daunorubicin Drugs 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 claims 1
- 229940121823 Checkpoint kinase 1 inhibitor Drugs 0.000 abstract 6
- KNLYIIWNKWDLJV-LLVKDONJSA-N n-[4-[(3r)-3-aminopiperidin-1-yl]-5-bromo-1h-pyrrolo[2,3-b]pyridin-3-yl]-2-cyclopropylacetamide Chemical compound C1[C@H](N)CCCN1C1=C(Br)C=NC2=C1C(NC(=O)CC1CC1)=CN2 KNLYIIWNKWDLJV-LLVKDONJSA-N 0.000 abstract 1
- WDIZGRVKAMHYBD-SNVBAGLBSA-N n-[4-[(3r)-3-aminopiperidin-1-yl]-5-bromo-1h-pyrrolo[2,3-b]pyridin-3-yl]-2-methylpropanamide Chemical compound C=12C(NC(=O)C(C)C)=CNC2=NC=C(Br)C=1N1CCC[C@@H](N)C1 WDIZGRVKAMHYBD-SNVBAGLBSA-N 0.000 abstract 1
- RTANGYAYUPFXFN-LLVKDONJSA-N n-[4-[(3r)-3-aminopiperidin-1-yl]-5-bromo-1h-pyrrolo[2,3-b]pyridin-3-yl]-3-methylbutanamide Chemical compound C=12C(NC(=O)CC(C)C)=CNC2=NC=C(Br)C=1N1CCC[C@@H](N)C1 RTANGYAYUPFXFN-LLVKDONJSA-N 0.000 abstract 1
- YHYDTSNIMTWMKK-CYBMUJFWSA-N n-[4-[(3r)-3-aminopiperidin-1-yl]-5-bromo-1h-pyrrolo[2,3-b]pyridin-3-yl]-5-methylpyridine-3-carboxamide Chemical compound CC1=CN=CC(C(=O)NC=2C3=C(N4C[C@H](N)CCC4)C(Br)=CN=C3NC=2)=C1 YHYDTSNIMTWMKK-CYBMUJFWSA-N 0.000 abstract 1
- BAZRWWGASYWYGB-SNVBAGLBSA-N n-[4-[(3r)-3-aminopiperidin-1-yl]-5-bromo-1h-pyrrolo[2,3-b]pyridin-3-yl]cyclopropanecarboxamide Chemical compound C1[C@H](N)CCCN1C1=C(Br)C=NC2=C1C(NC(=O)C1CC1)=CN2 BAZRWWGASYWYGB-SNVBAGLBSA-N 0.000 abstract 1
- XEEMHUAWQDDHFY-GFCCVEGCSA-N n-[4-[(3r)-3-aminopiperidin-1-yl]-5-bromo-1h-pyrrolo[2,3-b]pyridin-3-yl]pyridine-3-carboxamide Chemical compound C1[C@H](N)CCCN1C1=C(Br)C=NC2=C1C(NC(=O)C=1C=NC=CC=1)=CN2 XEEMHUAWQDDHFY-GFCCVEGCSA-N 0.000 abstract 1
- QPSFUWMJLHQROI-CYBMUJFWSA-N n-[5-bromo-4-[(3r)-3-(methylamino)piperidin-1-yl]-1h-pyrrolo[2,3-b]pyridin-3-yl]pyridine-3-carboxamide Chemical compound C1[C@H](NC)CCCN1C1=C(Br)C=NC2=C1C(NC(=O)C=1C=NC=CC=1)=CN2 QPSFUWMJLHQROI-CYBMUJFWSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 description 40
- 229940125782 compound 2 Drugs 0.000 description 25
- 229940125898 compound 5 Drugs 0.000 description 22
- 241000699660 Mus musculus Species 0.000 description 20
- 238000011580 nude mouse model Methods 0.000 description 20
- 241001465754 Metazoa Species 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 19
- 230000005764 inhibitory process Effects 0.000 description 17
- 210000004881 tumor cell Anatomy 0.000 description 16
- 230000037396 body weight Effects 0.000 description 15
- 241000699670 Mus sp. Species 0.000 description 11
- 230000026731 phosphorylation Effects 0.000 description 11
- 238000006366 phosphorylation reaction Methods 0.000 description 11
- 230000004614 tumor growth Effects 0.000 description 11
- 201000009030 Carcinoma Diseases 0.000 description 8
- 208000009956 adenocarcinoma Diseases 0.000 description 8
- 239000003981 vehicle Substances 0.000 description 8
- DVQHYTBCTGYNNN-UHFFFAOYSA-N azane;cyclobutane-1,1-dicarboxylic acid;platinum Chemical compound N.N.[Pt].OC(=O)C1(C(O)=O)CCC1 DVQHYTBCTGYNNN-UHFFFAOYSA-N 0.000 description 7
- 230000004071 biological effect Effects 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 206010041823 squamous cell carcinoma Diseases 0.000 description 7
- 238000007920 subcutaneous administration Methods 0.000 description 7
- 101150012716 CDK1 gene Proteins 0.000 description 6
- 101100059559 Emericella nidulans (strain FGSC A4 / ATCC 38163 / CBS 112.46 / NRRL 194 / M139) nimX gene Proteins 0.000 description 6
- 208000012766 Growth delay Diseases 0.000 description 6
- 101000777277 Homo sapiens Serine/threonine-protein kinase Chk2 Proteins 0.000 description 6
- 206010039491 Sarcoma Diseases 0.000 description 6
- 101100273808 Xenopus laevis cdk1-b gene Proteins 0.000 description 6
- 229940125904 compound 1 Drugs 0.000 description 6
- 208000008443 pancreatic carcinoma Diseases 0.000 description 6
- 230000005778 DNA damage Effects 0.000 description 5
- 231100000277 DNA damage Toxicity 0.000 description 5
- 230000033616 DNA repair Effects 0.000 description 5
- 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 description 5
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 5
- 102100031075 Serine/threonine-protein kinase Chk2 Human genes 0.000 description 5
- 206010041067 Small cell lung cancer Diseases 0.000 description 5
- 229940126214 compound 3 Drugs 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000003119 immunoblot Methods 0.000 description 5
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 5
- 201000002528 pancreatic cancer Diseases 0.000 description 5
- 208000000587 small cell lung carcinoma Diseases 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 101100002068 Bacillus subtilis (strain 168) araR gene Proteins 0.000 description 4
- MWWSFMDVAYGXBV-RUELKSSGSA-N Doxorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 MWWSFMDVAYGXBV-RUELKSSGSA-N 0.000 description 4
- 206010024612 Lipoma Diseases 0.000 description 4
- 101150044616 araC gene Proteins 0.000 description 4
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 4
- WBXPDJSOTKVWSJ-ZDUSSCGKSA-L pemetrexed(2-) Chemical compound C=1NC=2NC(N)=NC(=O)C=2C=1CCC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 WBXPDJSOTKVWSJ-ZDUSSCGKSA-L 0.000 description 4
- 230000008439 repair process Effects 0.000 description 4
- 201000008808 Fibrosarcoma Diseases 0.000 description 3
- 206010043276 Teratoma Diseases 0.000 description 3
- 230000022131 cell cycle Effects 0.000 description 3
- 201000011066 hemangioma Diseases 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- MOVBBVMDHIRCTG-LJQANCHMSA-N 4-[(3s)-1-azabicyclo[2.2.2]oct-3-ylamino]-3-(1h-benzimidazol-2-yl)-6-chloroquinolin-2(1h)-one Chemical compound C([N@](CC1)C2)C[C@@H]1[C@@H]2NC1=C(C=2NC3=CC=CC=C3N=2)C(=O)NC2=CC=C(Cl)C=C21 MOVBBVMDHIRCTG-LJQANCHMSA-N 0.000 description 2
- 206010001233 Adenoma benign Diseases 0.000 description 2
- 201000003076 Angiosarcoma Diseases 0.000 description 2
- 206010014733 Endometrial cancer Diseases 0.000 description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 description 2
- 208000002927 Hamartoma Diseases 0.000 description 2
- 208000001258 Hemangiosarcoma Diseases 0.000 description 2
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 2
- 208000018142 Leiomyosarcoma Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 2
- 208000008383 Wilms tumor Diseases 0.000 description 2
- 229940110282 alimta Drugs 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229940088954 camptosar Drugs 0.000 description 2
- 208000002458 carcinoid tumor Diseases 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 229940120655 eloxatin Drugs 0.000 description 2
- 201000003914 endometrial carcinoma Diseases 0.000 description 2
- 229960005420 etoposide Drugs 0.000 description 2
- 206010016629 fibroma Diseases 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 229940020967 gemzar Drugs 0.000 description 2
- 231100000024 genotoxic Toxicity 0.000 description 2
- 230000001738 genotoxic effect Effects 0.000 description 2
- 208000005017 glioblastoma Diseases 0.000 description 2
- 229940088013 hycamtin Drugs 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 201000010260 leiomyoma Diseases 0.000 description 2
- 208000003747 lymphoid leukemia Diseases 0.000 description 2
- 206010027191 meningioma Diseases 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 201000008968 osteosarcoma Diseases 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 2
- 208000017572 squamous cell neoplasm Diseases 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 229940061353 temodar Drugs 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 229940053867 xeloda Drugs 0.000 description 2
- IAYGCINLNONXHY-LBPRGKRZSA-N 3-(carbamoylamino)-5-(3-fluorophenyl)-N-[(3S)-3-piperidinyl]-2-thiophenecarboxamide Chemical compound NC(=O)NC=1C=C(C=2C=C(F)C=CC=2)SC=1C(=O)N[C@H]1CCCNC1 IAYGCINLNONXHY-LBPRGKRZSA-N 0.000 description 1
- VANHQTOUHVZHHF-IBGZPJMESA-N 5-[[5-[[(2s)-3-carboxy-1-[5-(2,6-dichlorophenyl)-1,3-oxazol-2-yl]-1-oxopropan-2-yl]carbamoyl]pyridin-2-yl]methylsulfamoyl]-2-hydroxybenzoic acid Chemical compound N([C@@H](CC(=O)O)C(=O)C=1OC(=CN=1)C=1C(=CC=CC=1Cl)Cl)C(=O)C(C=N1)=CC=C1CNS(=O)(=O)C1=CC=C(O)C(C(O)=O)=C1 VANHQTOUHVZHHF-IBGZPJMESA-N 0.000 description 1
- GMIZZEXBPRLVIV-SECBINFHSA-N 6-bromo-3-(1-methylpyrazol-4-yl)-5-[(3r)-piperidin-3-yl]pyrazolo[1,5-a]pyrimidin-7-amine Chemical compound C1=NN(C)C=C1C1=C2N=C([C@H]3CNCCC3)C(Br)=C(N)N2N=C1 GMIZZEXBPRLVIV-SECBINFHSA-N 0.000 description 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- 208000003200 Adenoma Diseases 0.000 description 1
- 206010001488 Aggression Diseases 0.000 description 1
- 206010061424 Anal cancer Diseases 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 101150006084 CHKB gene Proteins 0.000 description 1
- 101100220616 Caenorhabditis elegans chk-2 gene Proteins 0.000 description 1
- 208000009458 Carcinoma in Situ Diseases 0.000 description 1
- 208000010667 Carcinoma of liver and intrahepatic biliary tract Diseases 0.000 description 1
- 206010008263 Cervical dysplasia Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 108010019244 Checkpoint Kinase 1 Proteins 0.000 description 1
- 102000006459 Checkpoint Kinase 1 Human genes 0.000 description 1
- 108010019243 Checkpoint Kinase 2 Proteins 0.000 description 1
- 102000006457 Checkpoint Kinase 2 Human genes 0.000 description 1
- 201000005262 Chondroma Diseases 0.000 description 1
- 208000005243 Chondrosarcoma Diseases 0.000 description 1
- 208000006332 Choriocarcinoma Diseases 0.000 description 1
- 206010048832 Colon adenoma Diseases 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 102000003915 DNA Topoisomerases Human genes 0.000 description 1
- 108090000323 DNA Topoisomerases Proteins 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 208000007033 Dysgerminoma Diseases 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 208000007659 Fibroadenoma Diseases 0.000 description 1
- 206010053717 Fibrous histiocytoma Diseases 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 208000007569 Giant Cell Tumors Diseases 0.000 description 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 description 1
- 201000005409 Gliomatosis cerebri Diseases 0.000 description 1
- 206010018404 Glucagonoma Diseases 0.000 description 1
- 206010018691 Granuloma Diseases 0.000 description 1
- 206010019629 Hepatic adenoma Diseases 0.000 description 1
- 206010073069 Hepatic cancer Diseases 0.000 description 1
- 208000005045 Interdigitating dendritic cell sarcoma Diseases 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 208000002260 Keloid Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 208000002404 Liver Cell Adenoma Diseases 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 1
- 208000014767 Myeloproliferative disease Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 201000004404 Neurofibroma Diseases 0.000 description 1
- 201000010133 Oligodendroglioma Diseases 0.000 description 1
- 206010031149 Osteitis Diseases 0.000 description 1
- 208000000035 Osteochondroma Diseases 0.000 description 1
- 208000007641 Pinealoma Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 208000005678 Rhabdomyoma Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 206010061934 Salivary gland cancer Diseases 0.000 description 1
- 201000010208 Seminoma Diseases 0.000 description 1
- 208000000097 Sertoli-Leydig cell tumor Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 208000032383 Soft tissue cancer Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 208000009311 VIPoma Diseases 0.000 description 1
- 206010047741 Vulval cancer Diseases 0.000 description 1
- 208000004354 Vulvar Neoplasms Diseases 0.000 description 1
- 206010048214 Xanthoma Diseases 0.000 description 1
- 206010048215 Xanthomatosis Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000002718 adenomatoid tumor Diseases 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 201000007538 anal carcinoma Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 208000001119 benign fibrous histiocytoma Diseases 0.000 description 1
- 201000000053 blastoma Diseases 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 208000018339 bone inflammation disease Diseases 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 201000009480 botryoid rhabdomyosarcoma Diseases 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 201000003149 breast fibroadenoma Diseases 0.000 description 1
- 208000003362 bronchogenic carcinoma Diseases 0.000 description 1
- 201000002143 bronchus adenoma Diseases 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 230000025084 cell cycle arrest Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 201000005217 chondroblastoma Diseases 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 201000010305 cutaneous fibrous histiocytoma Diseases 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 231100000371 dose-limiting toxicity Toxicity 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 201000008184 embryoma Diseases 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 208000015419 gastrin-producing neuroendocrine tumor Diseases 0.000 description 1
- 201000000052 gastrinoma Diseases 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 208000006359 hepatoblastoma Diseases 0.000 description 1
- 201000002735 hepatocellular adenoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 201000004933 in situ carcinoma Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 206010022498 insulinoma Diseases 0.000 description 1
- 210000002570 interstitial cell Anatomy 0.000 description 1
- 201000010985 invasive ductal carcinoma Diseases 0.000 description 1
- 210000001117 keloid Anatomy 0.000 description 1
- 208000022013 kidney Wilms tumor Diseases 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 201000002250 liver carcinoma Diseases 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 201000005243 lung squamous cell carcinoma Diseases 0.000 description 1
- 208000019420 lymphoid neoplasm Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 201000000289 malignant teratoma Diseases 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000002418 meninge Anatomy 0.000 description 1
- 230000004001 molecular interaction Effects 0.000 description 1
- 208000010492 mucinous cystadenocarcinoma Diseases 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- 208000009091 myxoma Diseases 0.000 description 1
- IHPHPGLJYCDONF-UHFFFAOYSA-N n-propylacetamide Chemical compound CCCNC(C)=O IHPHPGLJYCDONF-UHFFFAOYSA-N 0.000 description 1
- 201000008026 nephroblastoma Diseases 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 208000007538 neurilemmoma Diseases 0.000 description 1
- 201000004662 neurofibroma of spinal cord Diseases 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 208000003388 osteoid osteoma Diseases 0.000 description 1
- 208000008798 osteoma Diseases 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical group C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 208000021255 pancreatic insulinoma Diseases 0.000 description 1
- 208000030940 penile carcinoma Diseases 0.000 description 1
- 201000008174 penis carcinoma Diseases 0.000 description 1
- 201000002628 peritoneum cancer Diseases 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 208000024724 pineal body neoplasm Diseases 0.000 description 1
- 201000004123 pineal gland cancer Diseases 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000008458 response to injury Effects 0.000 description 1
- 208000029922 reticulum cell sarcoma Diseases 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 201000003804 salivary gland carcinoma Diseases 0.000 description 1
- 206010039667 schwannoma Diseases 0.000 description 1
- 208000004548 serous cystadenocarcinoma Diseases 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 208000001608 teratocarcinoma Diseases 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 231100000816 toxic dose Toxicity 0.000 description 1
- 206010044412 transitional cell carcinoma Diseases 0.000 description 1
- 208000022271 tubular adenoma Diseases 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 208000012991 uterine carcinoma Diseases 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 210000003905 vulva Anatomy 0.000 description 1
- 201000005102 vulva cancer Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16856309P | 2009-04-11 | 2009-04-11 | |
| US168563P | 2009-04-11 | ||
| PCT/US2010/030634 WO2010118390A1 (en) | 2009-04-11 | 2010-04-09 | Checkpoint kinase 1 inhibitors for potentiating dna damaging agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2608656T3 true ES2608656T3 (es) | 2017-04-12 |
Family
ID=42651200
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES10721579.0T Active ES2608656T3 (es) | 2009-04-11 | 2010-04-09 | Inhibidores de quinasa de punto de control 1 para la potenciación de agentes que dañan el ADN |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP2416773B1 (https=) |
| JP (2) | JP5805071B2 (https=) |
| KR (1) | KR101676062B1 (https=) |
| CN (1) | CN102612365B (https=) |
| AU (1) | AU2010233122B2 (https=) |
| BR (1) | BRPI1013920A2 (https=) |
| CA (1) | CA2758300C (https=) |
| ES (1) | ES2608656T3 (https=) |
| IL (1) | IL215709A (https=) |
| MX (1) | MX341368B (https=) |
| NZ (1) | NZ596125A (https=) |
| RU (1) | RU2567044C2 (https=) |
| SG (3) | SG10201404012RA (https=) |
| WO (1) | WO2010118390A1 (https=) |
| ZA (1) | ZA201108273B (https=) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8841304B2 (en) | 2008-01-08 | 2014-09-23 | Array Biopharma, Inc. | Pyrrolopyridines as kinase inhibitors |
| CN101965347B (zh) | 2008-01-09 | 2013-01-02 | 阵列生物制药公司 | 作为激酶抑制剂的吡唑并吡啶 |
| US8481557B2 (en) | 2009-04-11 | 2013-07-09 | Array Biopharma Inc. | Method of treatment using checkpoint kinase 1 inhibitors |
| GB201008005D0 (en) | 2010-05-13 | 2010-06-30 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| ES2621857T3 (es) * | 2010-11-16 | 2017-07-05 | Array Biopharma, Inc. | Combinación de inhibidores de la cinasa 1 de punto de control e inhibidores de la cinasa WEE1 |
| GB201119799D0 (en) | 2011-11-16 | 2011-12-28 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| JP6606428B2 (ja) | 2013-10-11 | 2019-11-13 | 国立大学法人 東京医科歯科大学 | 脊髄小脳変性症を予防又は治療するための薬剤 |
| GB201402277D0 (en) | 2014-02-10 | 2014-03-26 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| EP3461480A1 (en) | 2017-09-27 | 2019-04-03 | Onxeo | Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer |
| TW202043198A (zh) * | 2019-01-17 | 2020-12-01 | 美商Ｉｆｍ Ｄｕｅ有限公司 | 用於治療與sting活性相關之病況的化合物及組合物 |
| KR102285996B1 (ko) * | 2019-08-08 | 2021-08-05 | 차의과학대학교 산학협력단 | 혈관신생을 억제하는 데 사용하기 위한 조성물 및 그 용도 |
| WO2021113661A1 (en) | 2019-12-05 | 2021-06-10 | Seagen Inc. | Amorphous and polymorphic form of a specific chk1 inhibitor |
| GB202107924D0 (en) | 2021-06-03 | 2021-07-21 | Sentinel Oncology Ltd | A pharmaceutical salt |
| UY39892A (es) | 2021-08-10 | 2023-03-31 | Novartis Pharma Ag | Compuestos y composiciones para tratar afecciones asociadas con la actividad de STING |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| IL326136A (en) | 2023-08-07 | 2026-03-01 | Revolution Medicines Inc | RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025217307A1 (en) | 2024-04-09 | 2025-10-16 | Revolution Medicines, Inc. | Methods for predicting response to a ras(on) inhibitor and combination therapies |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003028724A1 (en) * | 2001-10-04 | 2003-04-10 | Smithkline Beecham Corporation | Chk1 kinase inhibitors |
| EP1667684A1 (en) * | 2003-09-17 | 2006-06-14 | ICOS Corporation | Use of chk1 inhibitors to control cell proliferation |
| UY29177A1 (es) * | 2004-10-25 | 2006-05-31 | Astex Therapeutics Ltd | Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos |
| CN101415417A (zh) * | 2006-04-04 | 2009-04-22 | 辉瑞产品公司 | (2r,z)-2-氨基-2-环己基-n-(5-(1-甲基-1h-吡唑-4-基)-1-氧代-2,6-二氢-1h-[1,2]二氮杂卓并[4,5,6-cd]吲哚-8-基)乙酰胺的组合疗法 |
| WO2008063558A2 (en) * | 2006-11-17 | 2008-05-29 | Schering Corporation | Combination of an inhibitor of dna polymerase-alpha and an inhibitor of a checkpoint kinase for proliferative disorders |
| AR071717A1 (es) * | 2008-05-13 | 2010-07-07 | Array Biopharma Inc | Pirrolo[2,3-b]piridinas inhibidoras de quinasas chk1 y chk2,composiciones farmaceuticas que las contienen,proceso para prepararlas y uso de las mismas en el tratamiento y prevencion del cancer. |
-
2010
- 2010-04-09 SG SG10201404012RA patent/SG10201404012RA/en unknown
- 2010-04-09 CA CA2758300A patent/CA2758300C/en active Active
- 2010-04-09 MX MX2011010675A patent/MX341368B/es active IP Right Grant
- 2010-04-09 NZ NZ596125A patent/NZ596125A/xx not_active IP Right Cessation
- 2010-04-09 CN CN201080025806.6A patent/CN102612365B/zh not_active Expired - Fee Related
- 2010-04-09 BR BRPI1013920A patent/BRPI1013920A2/pt not_active Application Discontinuation
- 2010-04-09 KR KR1020117026769A patent/KR101676062B1/ko not_active Expired - Fee Related
- 2010-04-09 JP JP2012504909A patent/JP5805071B2/ja not_active Expired - Fee Related
- 2010-04-09 RU RU2011145773/15A patent/RU2567044C2/ru active
- 2010-04-09 SG SG2011075520A patent/SG175242A1/en unknown
- 2010-04-09 WO PCT/US2010/030634 patent/WO2010118390A1/en not_active Ceased
- 2010-04-09 SG SG10201900212QA patent/SG10201900212QA/en unknown
- 2010-04-09 AU AU2010233122A patent/AU2010233122B2/en not_active Ceased
- 2010-04-09 EP EP10721579.0A patent/EP2416773B1/en active Active
- 2010-04-09 ES ES10721579.0T patent/ES2608656T3/es active Active
-
2011
- 2011-10-11 IL IL215709A patent/IL215709A/en active IP Right Grant
- 2011-11-10 ZA ZA2011/08273A patent/ZA201108273B/en unknown
-
2014
- 2014-07-29 JP JP2014153687A patent/JP2014198741A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| JP5805071B2 (ja) | 2015-11-04 |
| SG175242A1 (en) | 2011-11-28 |
| SG10201900212QA (en) | 2019-02-27 |
| ZA201108273B (en) | 2013-07-31 |
| MX2011010675A (es) | 2012-03-16 |
| JP2014198741A (ja) | 2014-10-23 |
| CA2758300A1 (en) | 2010-10-14 |
| IL215709A (en) | 2017-06-29 |
| RU2011145773A (ru) | 2013-05-20 |
| CN102612365B (zh) | 2017-04-12 |
| BRPI1013920A2 (pt) | 2016-04-05 |
| KR20120004523A (ko) | 2012-01-12 |
| JP2012523435A (ja) | 2012-10-04 |
| AU2010233122A1 (en) | 2011-11-24 |
| RU2567044C2 (ru) | 2015-10-27 |
| IL215709A0 (en) | 2012-01-31 |
| SG10201404012RA (en) | 2014-09-26 |
| KR101676062B1 (ko) | 2016-11-14 |
| AU2010233122B2 (en) | 2015-09-17 |
| MX341368B (es) | 2016-08-17 |
| CA2758300C (en) | 2017-07-25 |
| NZ596125A (en) | 2012-08-31 |
| WO2010118390A1 (en) | 2010-10-14 |
| CN102612365A (zh) | 2012-07-25 |
| EP2416773A1 (en) | 2012-02-15 |
| EP2416773B1 (en) | 2016-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2608656T3 (es) | Inhibidores de quinasa de punto de control 1 para la potenciación de agentes que dañan el ADN | |
| US8481557B2 (en) | Method of treatment using checkpoint kinase 1 inhibitors | |
| ES2621857T3 (es) | Combinación de inhibidores de la cinasa 1 de punto de control e inhibidores de la cinasa WEE1 | |
| ES2818110T3 (es) | Tratamiento del cáncer con una combinación que comprende dinaciclib | |
| ES2719052T3 (es) | Terapia de combinación con un antibiótico antitumoral | |
| ES3049216T3 (en) | Methods and uses of the quinoline derivative anlotinib in the treatment of soft tissue sarcomas and pharmaceutical compositions for treatment of same | |
| ES2561202T3 (es) | Potenciación de quimioterapia contra el cáncer | |
| RU2015155283A (ru) | Фармацевтическая комбинация, содержащая метроформин и дигидрокверценин, и ее применение для лечения рака | |
| ES2405323T3 (es) | Tratamiento de melanoma | |
| Iratni et al. | Sildenafil in combination therapy against cancer: a literature review | |
| ES2248312T3 (es) | Composiciones que contienen una naftalmida y un agente aniproliferativo. | |
| Bennett et al. | Development of BT1718, a Bicycle Drug Conjugate®(BDC) targeting MT1-MMP for treatment of solid tumours | |
| HK1165273B (en) | Checkpoint kinase 1 inhibitors for potentiating dna damaging agents | |
| CN111773388A (zh) | A-失碳-5α雄甾烷化合物类药物与抗癌药物的联合应用 | |
| HK1183792B (en) | Combination of checkpoint kinase 1 inhibitors and wee 1 kinase inhibitors | |
| HK1183792A (en) | Combination of checkpoint kinase 1 inhibitors and wee 1 kinase inhibitors |